23720 Federal Register / Vol. 74, No. 96 / Wednesday, May 20, 2009 / Notices 

License Number: 017470NF. 

Name: CTX Expres, Inc. 

Address: 2450 W. Main St., #202, 

Alhambra, CA 91801. 

Date Revoked: April 30, 2009. 

Reason: Surrendered license 

voluntarily. 

License Number: 020068NF. 

Name: Ice Express LLC. dba Icexpress. 

Address: 120 Nassau Ave., Inwood, 

NY 11096. 

Date Revoked: May 1, 2009. 

Reason: Failed to maintain valid 

bonds. 

License Number: 020687NF. 

Name: MP Transmec USA LLC dba 

TS Lines. 

Address: 770 Foster Ave., 

Bensenville, IL 60106. 

Date Revoked: May 8, 2009. 

Reason: Failed to maintain valid 

bonds. 

License Number: 001593N. 

Name: Robertson Forwarding Co., Inc. 

dba RFC Consolidators. 

Address: 4469 NW 97th Ave., Miami, 

FL 33178. 

Date Revoked: May 10, 2009. 

Reason: Failed to maintain a valid 

bond. 

License Number: 013172F. 

Name: Yung Hoon Kim dba Conex 

International. 

Address: 20695 South Western Ave., 

Ste. 136, Torrance, CA 90501. 

Date Revoked: May 6, 2009. 

Reason: Failed to maintain a valid 

bond. 

Sandra L. Kusumoto, 

Director, Bureau of Certification and 

Licensing. 

[FR Doc. E9–11757 Filed 5–19–09; 8:45 am] 

BILLING CODE 6730–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Nominations to the Advisory 

Committee on Blood Safety and 

Availability 

AGENCY: Department of Health and 

Human Services, Office of the Secretary. 

ACTION: Notice. 

SUMMARY: The Office of Public Health 

and Science (OPHS) is seeking 

nominations of qualified individuals to 

be considered for appointment as 

members of the Advisory Committee on 

Blood Safety and Availability (ACBSA). 

ACBSA is a Federal advisory committee 

in the Department of Health and Human 

Services. Management support for the 

activities of this Committee is the 

responsibility of the OPHS. 

The qualified individuals will be 

nominated to the Secretary of Health 

and Human Services for consideration 

of appointment as members of the 

ACBSA. Members of the Committee, 

including the Chair, are appointed by 

the Secretary. Members are invited to 

serve on the Committee for up to fouryear terms. 

DATES: All nominations must be 

received no later than 4 p.m. EDT on 

June 30, 2009, at the address listed 

below. 

ADDRESSES: All nominations should be 

mailed or delivered to Dr. Jerry 

Holmberg, Executive Secretary, 

Advisory Committee on Blood Safety 

and Availability, Office of Public Health 

and Science, Department of Health and 

Human Services, 1101 Wootton 

Parkway, Suite 250, Rockville, MD 

20852. Telephone: (240) 453–8803. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Jerry Holmberg, Executive Secretary, 

Advisory Committee on Blood Safety 

and Availability, Office of Public Health 

and Science, Department of Health and 

Human Services, 1101 Wootton 

Parkway, Suite 250, Rockville, MD 

20852. Telephone: (240) 453–8803. 

A copy of the Committee charter and 

roster of the current membership can be 

obtained by contacting Dr. Holmberg or 

by accessing the ACBSA Web site at 

http://www.hhs.gov/bloodsafety. http:// 

www.hhs.gov/bloodsafety. 

SUPPLEMENTARY INFORMATION: The 

Advisory Committee on Blood Safety 

and Availability advises the Secretary 

and the Assistant Secretary for Health. 

The Committee provides advice on a 

range of policy issues to include: (1) 

Definition of public health parameters 

around safety and availability of the 

blood and blood products, (2) broad 

public health, ethical, and legal issues 

related to transfusion and 

transplantation safety, and (3) the 

implications for safety and availability 

of various economic factors affecting 

product cost and supply. 

The ACBSA consists of 20 voting 

members. The Committee is composed 

of 14 public members, including the 

Chair, and six (6) representative 

members. The public members are 

selected from State and local 

organizations, advocacy groups, 

provider organizations, academic 

researchers, ethicists, private 

physicians, scientists, consumer 

advocates, legal organizations, and from 

among communities of persons who are 

frequent recipients of blood or blood 

products. There are six (6) individuals 

designated to serve as official 

representative members of the blood 

and blood products industry or 

professional organizations. These 

representative members shall be from 

AABB (formerly the American 

Association of Blood Banks), Plasma 

Protein Therapeutic Association 

(PPTA), one of the two major 

distributors of blood on a rotating basis, 

a trade organization or manufacturer of 

blood, plasma, or other tissue test kits 

or equipment, and a major hospital 

organization that purchases blood and 

blood products. 

All ACBSA members are authorized 

to receive the prescribed per diem 

allowance and reimbursement for travel 

expenses that are incurred to attend 

meetings and conduct Committeerelated business, in accordance with 

Standard Government Travel 

Regulations. Individuals who are 

appointed to serve as public members 

are authorized also to receive a stipend 

for attending Committee meetings and 

to carry out other Committee-related 

business. Individuals who are appointed 

to serve as representative members for a 

particular interest group or industry are 

not authorized to receive a stipend for 

the performance of these duties. 

This announcement is to solicit 

nominations of qualified candidates to 

fill positions on the ACBSA that are 

scheduled to be vacated in the public 

member category. The positions are 

scheduled to be vacated on March 1, 

2010. 

Nominations 

Persons nominated for appointment 

as members of the ACBSA should be 

among authorities knowledgeable in 

blood banking, transfusion medicine, 

plasma therapies, transfusion and 

transplantation safety, bioethics, and/or 

related disciplines. Nominations should 

be typewritten. The following 

information should be included in the 

package of material submitted for each 

individual being nominated for 

consideration of appointment: (a) The 

name, return address, daytime 

telephone number and affiliation(s) of 

the individual being nominated, the 

basis for the individual’s nomination, 

the category for which the individual is 

being nominated, and a statement 

bearing an original signature of the 

nominated individual that, if appointed, 

he or she is willing to serve as a member 

of the Committee; (b) the name, return 

address, and daytime telephone number 

at which the nominator may be 

contacted. Organizational nominators 

must identify a principal contact person 

in addition to the contact; and (c) a copy 

of a current curriculum vitae or resume 

for the nominated individual. 

Individuals can nominate themselves 

for consideration of appointment to the 

Committee. All nominations must 

include the required information. 

Federal Register / Vol. 74, No. 96 / Wednesday, May 20, 2009 / Notices 23721 

Incomplete nominations will not be 

processed for consideration. The letter 

from the nominator and certification of 

the nominated individual must bear 

original signatures; reproduced copies 

of these signatures are not acceptable. 

The Department of Health and Human 

Services is committed to ensuring that 

women, minority groups, and physically 

challenged individuals are adequately 

represented on the Committee. 

Nominations of qualified candidates 

from these categories are encouraged. 

The Department also seeks to have 

geographic diversity reflected in the 

composition of the Committee. 

The Standards of Ethical Conduct for 

Employees of the Executive Branch are 

applicable to individuals who are 

appointed as public members of Federal 

advisory committees. Individuals 

appointed to serve as public members of 

Federal advisory committees are 

classified as special Government 

employees (SGEs). SGEs are 

Government employees for purposes of 

the conflict of interest laws. Therefore, 

individuals appointed to serve as public 

members of the ACBSA are subject to an 

ethics review. The ethics review is 

conducted to determine if the 

individual has any interests and/or 

activities in the private sector that may 

conflict with performance of their 

official duties as a member of the 

Committee. Individuals appointed to 

serve as public members of the 

Committee will be required to disclose 

information regarding financial 

holdings, consultancies, and research 

grants and/or contracts. 

Dated: May 14, 2009. 

Jerry A. Holmberg, 

Executive Secretary, Advisory Committee on 

Blood Safety and Availability. 

[FR Doc. E9–11675 Filed 5–19–09; 8:45 am] 

BILLING CODE 4150–41–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Submission for OMB Review; 

Comment Request 

Title: Extension to HS Transportation 

Requirement. 

OMB No.: 0970–0260. 

Description: The Office of Head Start 

is proposing to renew authority to 

collect information regarding the Head 

Start transportation requirement 

without changes. The transportation 

requirement provides the requirement 

that each child be seated in a child 

restraint system while the vehicle is in 

motion, and the requirement that each 

bus have at least one bus monitor on 

board at all times. Waivers would be 

granted when the Head Start or Early 

Head Start grantee demonstrates that 

compliance with the requirement(s) for 

which the waiver is being sought will 

result in a significant disruption to the 

Head Start program or the Early Head 

Start program and that waiving the 

requirement(s) is in the best interest of 

the children involved. 

Respondents: Head Start and Early 

Head Start program grants recipients. 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden hours 

per response 

Total burden 

hours 

Form ................................................................................................................. 275 1 1 275 

Estimated Total Annual Burden 

Hours: 275. 

Additional Information: Copies of the 

proposed collection may be obtained by 

writing to the Administration for 

Children and Families, Office of 

Administration, Office of Information 

Services, 370 L’Enfant Promenade, SW., 

Washington, DC 20447, Attn: ACF 

Reports Clearance Officer. All requests 

should be identified by the title of the 

information collection. E-mail address: 

infocollection@acf.hhs.gov. 

OMB Comment: OMB is required to 

make a decision concerning the 

collection of information between 30 

and 60 days after publication of this 

document in the Federal Register. 

Therefore, a comment is best assured of 

having its full effect if OMB receives it 

within 30 days of publication. Written 

comments and recommendations for the 

proposed information collection should 

be sent directly to the following: Office 

of Management and Budget, Paperwork 

Reduction Project, Fax: 202–395–7245, 

Attn: Desk Officer for the 

Administration for Children and 

Families. 

Dated: May 14, 2009. 

Janean Chambers, 

Reports Clearance Officer. 

[FR Doc. E9–11652 Filed 5–19–09; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2008–N–0546] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Electronic Data 

Collection Using MedWatchPlus Portal 

and Rational Questionnaire 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a proposed collection of 

information has been submitted to the 

Office of Management and Budget 

(OMB) for review and clearance under 

the Paperwork Reduction Act of 1995 

(the PRA). 

DATES: Fax written comments on the 

collection of information by June 19, 

2009. 

ADDRESSES: To ensure that comments on 

the information collection are received, 

OMB recommends that written 

comments be faxed to the Office of 

Information and Regulatory Affairs, 

OMB, Attn: FDA Desk Officer, FAX: 

202–395–6974, or e-mailed to 

oira_submission@omb.eop.gov. All 

comments should be identified with the 

OMB control number 0910–NEW and 

title ‘‘Electronic Data Collection Using 

MedWatchPlus Portal and Rational 

Questionnaire.’’ Also include the FDA 

docket number found in brackets in the 

heading of this document. 

FOR FURTHER INFORMATION CONTACT: 

Jonna Capezzuto, Office of Information 

Management (HFA–710), Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857, 301–796–3794. 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, FDA 

has submitted the following proposed